论文部分内容阅读
垂体腺瘤单克隆起源于垂体腺细胞,是蝶鞍区最常见的肿瘤。其发病率约为颅内肿瘤的22.5%,仅次于胶质瘤和脑膜瘤。大多数的垂体腺瘤为良性,仅0.1%的垂体腺瘤会进展为垂体癌。目前垂体腺瘤发病机制还不清楚。微小RNA(miRNA)是短片段的非编码RNA,主要在转录后水平调控基因的表达。大量报道证实miRNA的紊乱表达与垂体腺瘤密切相关。为此,本文对miRNA影响垂体腺瘤行为学及其作用机制以及miRNA相关药物治疗垂体腺瘤进行简要综述。
Pituitary adenoma monoclonal origin from the pituitary gland cells, is the most common tumor of the sella region. The incidence of intracranial tumors is about 22.5%, second only to glioma and meningioma. Most pituitary adenomas are benign, and only 0.1% of pituitary adenomas progress to pituitary adenocarcinoma. The pathogenesis of pituitary adenomas is unclear. MicroRNAs (miRNAs) are short segment non-coding RNAs that regulate gene expression mainly at the post-transcriptional level. A large number of reports confirm that miRNA expression is closely related to pituitary adenomas. To this end, this article on the miRNA impact on the behavior of pituitary adenomas and its mechanism of action and miRNA-related drugs for the treatment of pituitary adenoma were briefly reviewed.